NASDAQ · TECH

Bio – Techne Corp.

$71.60 -$0.17 (-0.24%) 1D After hours

Key Metrics

$11.18B
Market cap
102.06×
P/E · TTM
$1.21B
Revenue · TTM
$109.56M
Net income
EPS · TTM $0.70
Dividend yield 0.4%
Free cash flow $269.60M
Beta · 1Y 0.94
EBITDA · TTM $247.47M
Gross margin 65.0%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 25
    The stock moved +20.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 25
  • May 15
    From its Feb 4 high, the share price fell 37%.

    Peak close $68.67 on Feb 4; trough close $43.30 on May 15. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -37%
  • May 6
    The stock moved -16.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 6

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$11.18B
Enterprise value$11.17B
Shares outstanding155.8M
52-wk range$43.20 – $72.16
Avg volume · 20D1.4M
Net cash $9.82M
Book value / share$13.29
IndustryBiological Products, (No Diagnostic Substances)
ExchangeNASDAQ
About Bio – Techne Corp.
IPO dateMay 8, 1989
Employees3100

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%).

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E102.06
P/S9.24
P/FCF41.48
EV/EBITDA45.15
EV/Sales9.23
Graham №$14.45

Profitability

Gross 65.0%
Operating 12.2%
Net 9.0%
FCF 22.3%
ROE / ROIC 5.3% · 5.3%

Financial Health

Current ratio4.49
Quick ratio3.18
Debt / equity0.10
Debt / EBITDA 0.81Low leverage
Net cash $9.82M
Working capital$534.77M

Cash Flow · TTM

Operating CF $294.86M
Capex −$25.26M
Free cash flow $269.60M
Buybacks $100.08M
Dividends paid $49.82M
Shareholder yield 1.3%

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

$14.45 vs $71.60
Trades 5.0× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings